Listing of the Claims

This listing of claims reflects the claims as they currently stand in this application:

Listing of the Claims:

1-19 (Cancelled)

20. (Previously presented) An isolated polynucleotide which encodes a GLP-2 receptor selected from:
(a) a human GLP-2 receptor comprising the amino acid sequence of amino acids 67-553 of SEQ ID NO:12; and
(b) a GLP-2 receptor which is at least 95% identical to amino acids 26-553 of SEQ ID NO:12 and which exhibits the functional characteristic of selectively binding GLP-2.

21. (Previously Presented) An isolated polynucleotide which encodes a GLP-2 receptor according to claim 20 wherein said GLP-2 receptor is a human GLP-2 receptor comprising the amino acid sequence of amino acids 67-553 of SEQ ID NO:12.

22. (Previously Presented) An isolated polynucleotide according to claim 20, comprising nucleotides 320-1780 of SEQ ID NO:11.

23. (Previously Presented) An isolated polynucleotide according to claim 20, wherein said polynucleotide encodes a variant of said human GLP-2 receptor, said variant comprising a substitution of Arg85.

24. (Previously Presented) An isolated polynucleotide according to claim 23, which encodes a Glu85 variant.

25. (Cancelled)

26. (Currently amended) An isolated polynucleotide according to claim 20, wherein said polynucleotide encodes for the human GLP-2 receptor of amino acids 26-553 of SEQ ID NO[[.]]:12.

27. (Currently amended) An isolated polynucleotide according to claim 20, wherein said polynucleotide encodes for the human GLP-2 receptor and said polynucleotide encodes for the amino acid sequence which is at least 95% identical to amino acids 26-553 of SEQ ID NO:12.

28-31 (Cancelled)

32. (Previously Presented) In labeled form, a polynucleotide selected from a polynucleotide as defined in claim 20.

33. (Previously Presented) A recombinant polynucleotide comprising a GLP-2 receptor-encoding polynucleotide as defined in claim 20, and expression controlling elements linked operably therewith to drive expression thereof.

34. (Previously Presented) A cell that has been genetically engineered by the incorporation expressibly therein of a polynucleotide according to claim 20.

35. (Previously Presented) The cell according to claim 34, which is a mammalian cell.

36. (Previously Presented) An antibody which selectively binds to a GLP-2 receptor coded for by the polynucleotide according to claim 28.

37. (Previously Presented) A cell membrane preparation derived from a cell according to claim 34.

38. (Previously Presented) A method for identifying GLP-2 receptor ligands comprising:
(a) incubating a candidate ligand with a cell as defined in claim 35 or with a membrane preparation obtained therefrom, and then
(b) determining whether binding between the GLP-2 receptor and the candidate ligand has occurred.

39. (Previously Presented) A method for identifying GLP-2 receptor ligands, comprising the steps of:
(a) identifying a cell expressing a functional GLP-2 receptor comprising the amino acid sequence of amino acids 67-553 of SEQ ID NO:12,
(b) incubating a candidate ligand with the cell that expresses a functional GLP-2 receptor, or with a membrane preparation derived from said cell; and
(c) determining whether binding between the GLP-2 receptor and the ligand has occurred.

40. (Currently amended) A method according to claim 39, wherein the candidate ligand is incubated with a cell that produces a functional GLP-2 receptor, and the determination whether binding has occurred between the GLP-2 receptor and the candidate ligand ~~candidate~~ is achieved by measuring change in the intracellular cAMP level, an increase in the cAMP level indicating that the candidate ligand is a GLP-2 agonist.

41-42. (Cancelled)

43. (Previously Presented) An isolated polynucleotide according to claim 20, wherein said nucleotide sequence has at least 95% sequence identity to nucleotides 320-1780 of SEQ ID NO:11, wherein said polynucleotide encodes a mammalian GLP-2 receptor that exhibits the functional characteristics of selectively binding GLP-2.